Source-grounded facts extracted from QUEST DIAGNOSTICS INC's SEC 8-K filings across all families, newest first. Each cites a verbatim SEC excerpt.
QUEST DIAGNOSTICS INC shareholders rejected Stockholder proposal regarding an independent board chairman at the 2026-05-20 meeting.
“The stockholder proposal regarding an independent board chairman was not approved by the following votes: FOR AGAINST ABSTAIN NON-VOTES 23,999,636 69,792,819 407,290 9,135,906”
QUEST DIAGNOSTICS INC shareholders approved Ratification of appointment of PricewaterhouseCoopers as independent registered public accounting firm for 2026 at the 2026-05-20 meeting.
“The ratification of the appointment of PricewaterhouseCoopers as the Company’s independent registered public accounting firm for 2026 was approved by the following votes: FOR AGAINST ABSTAIN 97,340,034 5,809,995 185,622”
QUEST DIAGNOSTICS INC shareholders approved Advisory resolution to approve executive officer compensation at the 2026-05-20 meeting.
“The advisory resolution to approve the executive officer compensation disclosed in the Company’s 2026 Proxy Statement was approved by the following votes: FOR AGAINST ABSTAIN NON-VOTES 86,869,738 7,152,448 177,559 9,135,906”
QUEST DIAGNOSTICS INC shareholders approved Election of Directors at the 2026-05-20 meeting.
“The following nominees for the office of director were elected for terms expiring at the 2027 Annual Meeting of Stockholders, by the following votes: FOR AGAINST ABSTAIN NON-VOTES Robert B. Carter 93,821,069 205,166 173,510 9,135,906 James E. Davis 88,799,800 5,237,756 162,189 9,135,906 Luis A. Diaz, Jr., M.D. 93,909,369 110,114 180,262 9,135,906 Tracey C. Doi 93,649,938 393,268 156,539 9,135,906 Vicky B. Gregg 83,814,387 10,232,574 152,784 9,135,906 Wright L. Lassiter, III 93,802,306 223,154 174,285 9,135,906 Timothy L. Main 88,302,767 5,614,920 282,058 9,135,906 Denise M. Morrison 89,808,461 4,176,407 214,877 9,135,906 Gary M. Pfeiffer 86,302,153 7,716,970 180,622 9,135,906 Timothy M. Ring 81,917,543 11,994,424 287,778 9,135,906 Timothy C. Wentworth 93,427,490 597,095 175,160 9,135,906”
QUEST DIAGNOSTICS INC entered into Indenture with The Bank of New York Mellon valued at $500,000,000 aggregate principal amount (effective 2026-05-06).
“On May 6, 2026, Quest Diagnostics Incorporated (the “Company”) issued $500,000,000 aggregate principal amount of 5.000% senior notes due 2036 (the “Notes”).”
QUEST DIAGNOSTICS INC reported the quarter ended March 31, 2026 results: revenue $2,895, net income $252, EPS $2.24. Guidance raised.
“implement our first wave of solutions in the fall of 2027. 1 Three Months Ended March 31, 2026 2025 Change (dollars in millions, except per share data) Reported: Net revenues $ 2,895 $ 2,652 9.2 % Diagnostic Information Services revenues $ 2,832 $ 2,589 9.4 % Revenue per requisition (1.3) % Requisition volume 10.9 % Organic requisition volume 10.8 % Operating”
Robert B. Carter was elected as Director at QUEST DIAGNOSTICS INC.
“On May 16, 2024, the Board of Directors (the “Board”) of Quest Diagnostics Incorporated (the “Company”), after considering the recommendation of the Board’s Governance Committee, elected Robert B. Carter to the Board.”
QUEST DIAGNOSTICS INC reported the quarter ended March 31, 2024 results: revenue $2,366, net income $194, EPS $1.72. Guidance raised.
“adjusted earnings guidance for the full year," Mr. Davis said. Three Months Ended March 31, 2024 2023 Change (dollars in millions, except per share data) Reported: Net revenues $ 2,366 $ 2,331 1.5 % Diagnostic Information Services revenues $ 2,298 $ 2,259 1.7 % Revenue per requisition 0.1 % Requisition volume 1.6 % Organic requisition volume 1.0 % Operating”
QUEST DIAGNOSTICS INC reported quarter and full year ended December 31, 2023 results: revenue Fourth quarter revenues of $2.29 billion, EPS Fourth quarter reported diluted earnings per share ("EPS") of $1.70. Guidance initiated.
“Fourth Quarter and Full Year 2023 Financial Results; Provides Guidance for Full Year 2024; Increases Quarterly Dividend 5.6% to $0.75 Per Share • Fourth quarter revenues of $2.29 billion, down 1.9% from 2022 • Fourth quarter reported diluted earnings per share ("EPS") of $1.70, up 95.4% from 2022; and adjusted diluted EPS of $2.15, up 8.6% from 2022 • Fourth”
QUEST DIAGNOSTICS INC entered into Indenture with The Bank of New York Mellon valued at $750,000,000 aggregate principal amount (effective 2023-11-01).
“On November 1, 2023, Quest Diagnostics Incorporated (the “Company”) issued $750,000,000 aggregate principal amount of 6.400% senior notes due 2033 (the “Notes”).”
QUEST DIAGNOSTICS INC updated its Full Year 2023 guidance (reaffirmed).
“The company updates its Full Year 2023 guidance as follows: Updated Guidance Prior Guidance Low High Low High Net revenues $9.19 billion $9.24 billion $9.12 billion $9.22 billion Net revenues decrease (7.0)% (6.5)% (7.7)% (6.7)% Base business revenues (a) $8.99 billion $9.04 billion $8.92 billion $9.02 billion Base business revenues increase 6.7% 7.3% 5.8% 7.0% COVID-19 testing revenues Approximately $200 million Approximately $200 million COVID-19 testing revenues decrease (86.2)% (86.2)% Reported diluted EPS $7.61 $7.71 $7.52 $7.92 Adjusted diluted EPS $8.65 $8.75 $8.50 $8.90 Cash provided by operations Approximately $1.3 billion At least $1.3 billion Capital expenditures Approximately $400 million Approximately $400 million”
QUEST DIAGNOSTICS INC reported the quarter ended September 30, 2023 results: revenue $2,295, net income $225, EPS $1.96.
“growth.” Three Months Ended September 30, Nine Months Ended September 30, 2023 2022 Change 2023 2022 Change (dollars in millions, except per share data) Reported: Net revenues $ 2,295 $ 2,486 (7.7) % $ 6,964 $ 7,550 (7.8) % Base business revenues (a) $ 2,269 $ 2,170 4.6 % $ 6,778 $ 6,280 7.9 % COVID-19 testing revenues $ 26 $ 316 (92.0) % $ 186 $ 1,270 (85.4) %”
QUEST DIAGNOSTICS INC reported Full Year 2023 results: revenue $9.12 billion to $9.22 billion, EPS $7.52 to $7.92. Guidance raised.
“Updated Guidance for Full Year 2023 The company updates its Full Year 2023 guidance as follows: Updated Guidance Prior Guidance Low High Low High Net revenues $9.12 billion $9.22 billion $8.93 billion $9.08 billion”
QUEST DIAGNOSTICS INC reported the quarter ended June 30, 2023 results: revenue $2,338, net income $235, EPS $2.05. Guidance raised.
“tight labor market." Three Months Ended June 30, Six Months Ended June 30, 2023 2022 Change 2023 2022 Change (dollars in millions, except per share data) Reported: Net revenues $ 2,338 $ 2,453 (4.7) % $ 4,669 $ 5,064 (7.8) % Base business revenues (a) $ 2,297 $ 2,098 9.5 % $ 4,509 $ 4,110 9.7 % COVID-19 testing revenues $ 41 $ 355 (88.3) % $ 160 $ 954 (83.2) %”
QUEST DIAGNOSTICS INC shareholders rejected Stockholder proposal regarding a report on the Company's greenhouse gas emissions at the 2023-05-17 meeting.
“The stockholder proposal regarding a report on the Company's greenhouse gas emissions was not approved by the following votes: For Against Abstain Broker Non-Vote 44,199,216 47,876,708 619,695 9,597,043”
QUEST DIAGNOSTICS INC shareholders approved Amended and Restated Employee Long-Term Incentive Plan at the 2023-05-17 meeting.
“The Company's Amended and Restated Employee Long-Term Incentive Plan was approved by the following votes: For Against Abstain Broker Non-Vote 82,002,261 10,368,567 324,794 9,597,040”
QUEST DIAGNOSTICS INC shareholders approved Ratification of appointment of PricewaterhouseCoopers as independent registered public accounting firm for 2023 at the 2023-05-17 meeting.
“The ratification of the appointment of PricewaterhouseCoopers as the Company’s independent registered public accounting firm for 2023 was approved by the following votes: For Against Abstain 95,957,547 5,965,955 369,160”
QUEST DIAGNOSTICS INC shareholders approved Frequency of stockholder advisory vote to approve executive officer compensation at the 2023-05-17 meeting.
“The holders of record of the number of shares indicated below, all of which were entitled to vote at the Meeting, voted as follows in respect of the frequency of the stockholder advisory vote to approve executive officer compensation: 1 Year 2 Years 3 Years Abstain Broker Non-Vote 89,353,288 315,914 2,809,336 217,081 9,597,043”
QUEST DIAGNOSTICS INC shareholders approved Advisory resolution to approve executive officer compensation at the 2023-05-17 meeting.
“The advisory resolution to approve the executive officer compensation disclosed in the Company’s 2023 Proxy Statement was approved by the following votes: For Against Abstain Broker Non-Vote 83,289,135 9,124,611 281,877 9,597,039”
QUEST DIAGNOSTICS INC shareholders approved Election of directors at the 2023-05-17 meeting.
“The following nominees for the office of director were elected for terms expiring at the 2024 Annual Meeting of Stockholders, by the following votes: For Against Abstain Broker Non-Vote James E. Davis 85,997,737 5,982,924 714,967 9,597,034 Luis A. Diaz, Jr., M.D. 92,145,195 250,096 300,338 9,597,033 Tracey C. Doi 92,004,702 442,084 248,845 9,597,031 Vicky B. Gregg 88,898,904 3,547,388 249,344 9,597,026 Wright L. Lassiter, III 91,923,074 466,113 306,444 9,597,031 Timothy L. Main 91,828,624 579,027 287,975 9,597,036 Denise M. Morrison 90,882,798 1,560,142 252,694 9,597,028 Gary M. Pfeiffer 85,281,504 7,110,362 303,763 9,597,033 Timothy M. Ring 88,098,639 4,247,551 349,436 9,597,036 Gail R. Wilensky 87,289,170 4,864,508 541,953 9,597,031”
QUEST DIAGNOSTICS INC reported Full Year 2023 results: revenue $8.93 billion $9.08 billion, EPS $7.52 $8.02. Guidance lowered.
“Full year 2023 revenues now expected to be between $8.93 billion and $9.08 billion; reported diluted EPS now expected to be between $7.52 and $8.02”
QUEST DIAGNOSTICS INC updated its the quarter ended March 31, 2023 guidance (reaffirmed).
“On April 27, 2023, Quest Diagnostics Incorporated (the "Company") issued a press release announcing, among other things, its results for the quarter ended March 31, 2023.”
QUEST DIAGNOSTICS INC reported Full year 2023 results: revenue $8.83 billion $9.03 billion, EPS $7.61 $8.21. Guidance initiated.
“We estimate full year 2023 guidance as follows: Low High Net revenues $8.83 billion $9.03 billion Net revenues decrease (10.7)% (8.6)% Base business revenues (a) $8.65 billion $8.75 billion Base business revenues increase 2.6% 3.8% COVID-19 testing revenues $175 million $275 million COVID-19 testing revenues decrease (88.0)% (81.1)% Reported diluted EPS $7.61 $8.21 Adjusted diluted EPS $8.40 $9.00 Cash provided by operations At least $1.3 billion Capital expenditures Approximately $400 million”
QUEST DIAGNOSTICS INC reported Full year ended December 31, 2022 results: revenue $9.88 billion, net income $946 million, EPS $7.97.
“Full year revenues of $9.88 billion, down 8.4% from 2021 • Full year reported diluted EPS of $7.97, down 48.7% from 2021; and adjusted diluted EPS of $9.95, down 30.1% from 2021”
QUEST DIAGNOSTICS INC reported Three Months Ended December 31, 2022 results: revenue $2.33 billion, net income $101 million, EPS $0.87.
“Fourth quarter revenues of $2.33 billion, down 15.0% from 2021 • Fourth quarter reported diluted earnings per share ("EPS") of $0.87, down 72.1% from 2021; and adjusted diluted EPS of $1.98, down 40.5% from 2021”
QUEST DIAGNOSTICS INC: Amended and restated By-Laws to revise Sections 1.05, 1.06 and 1.07 regarding director nominations and proxy solicitations, including compliance with Rule 14a-19, and incorporate ministerial, clarifying and conforming changes (effective 2022-11-14).
“On November 14, 2022, the Board of Directors (the “Board”) of the Company amended and restated the Company's By-Laws (the "By-Laws"). The amendments (a) revise Sections 1.05, 1.06 and 1.07 with respect to nominations of directors and solicitations of proxies, including compliance with Rule 14a-19 under the Securities Exchange Act of 1934, as amended, and (b) incorporate ministerial, clarifying and conforming changes.”
Patrick T. Plewman was appointed as Senior Vice President for Diagnostic Services at QUEST DIAGNOSTICS INC.
“On November 16, 2022, Mark E. Delaney, Senior Vice President and Chief Commercial Officer; Mark A. Gardner, Senior Vice President, Molecular Genomics and Oncology; Karthik Kuppusamy, Senior Vice President, Clinical Solutions and Patrick T. Plewman, Senior Vice President for Diagnostic Services, became executive officers of Quest Diagnostics Incorporated (the "Company) and became Schedule B participants in the Company's Executive Officer Severance Plan (the "Plan").”
Karthik Kuppusamy was appointed as Senior Vice President, Clinical Solutions at QUEST DIAGNOSTICS INC.
“On November 16, 2022, Mark E. Delaney, Senior Vice President and Chief Commercial Officer; Mark A. Gardner, Senior Vice President, Molecular Genomics and Oncology; Karthik Kuppusamy, Senior Vice President, Clinical Solutions and Patrick T. Plewman, Senior Vice President for Diagnostic Services, became executive officers of Quest Diagnostics Incorporated (the "Company) and became Schedule B participants in the Company's Executive Officer Severance Plan (the "Plan").”
Mark A. Gardner was appointed as Senior Vice President, Molecular Genomics and Oncology at QUEST DIAGNOSTICS INC.
“On November 16, 2022, Mark E. Delaney, Senior Vice President and Chief Commercial Officer; Mark A. Gardner, Senior Vice President, Molecular Genomics and Oncology; Karthik Kuppusamy, Senior Vice President, Clinical Solutions and Patrick T. Plewman, Senior Vice President for Diagnostic Services, became executive officers of Quest Diagnostics Incorporated (the "Company) and became Schedule B participants in the Company's Executive Officer Severance Plan (the "Plan").”
Mark E. Delaney was appointed as Senior Vice President and Chief Commercial Officer at QUEST DIAGNOSTICS INC.
“On November 16, 2022, Mark E. Delaney, Senior Vice President and Chief Commercial Officer; Mark A. Gardner, Senior Vice President, Molecular Genomics and Oncology; Karthik Kuppusamy, Senior Vice President, Clinical Solutions and Patrick T. Plewman, Senior Vice President for Diagnostic Services, became executive officers of Quest Diagnostics Incorporated (the "Company) and became Schedule B participants in the Company's Executive Officer Severance Plan (the "Plan").”
Stephen H. Rusckowski changed role as Chairman of the Board at QUEST DIAGNOSTICS INC.
“Mr. Davis became Chief Executive Officer and President of the Company, and Stephen H. Rusckowski remains Chairman of the Company”
James E. Davis was elected as Director at QUEST DIAGNOSTICS INC.
“elected James E. Davis to fill the resulting vacancy”
James E. Davis was appointed as Chief Executive Officer and President at QUEST DIAGNOSTICS INC.
“Mr. Davis became Chief Executive Officer and President of the Company, and Stephen H. Rusckowski remains Chairman of the Company”
James Davis changed role as Chief Executive Officer and President at QUEST DIAGNOSTICS INC.
“On October 28, 2022, the Compensation Committee (the “Committee”) of the Board of Directors of Quest Diagnostics Incorporated (the “Company”) approved an updated compensation package for Mr. Davis, reflecting Mr. Davis becoming Chief Executive Officer and President of the Company.”
Stephen H. Rusckowski retired as Executive Chairman at QUEST DIAGNOSTICS INC.
“Mr. Rusckowski’s arrangements in connection with his retirement as Chief Executive Officer and President on November 1, 2022 and his service as Executive Chairman of the Company until March 31, 2023.”
Mark Guinan departed as Chief Financial Officer at QUEST DIAGNOSTICS INC.
“Mr. Samad succeeds Mark Guinan, who, in February 2022, announced his decision to retire.”
Sam Samad was appointed as Executive Vice President and Chief Financial Officer at QUEST DIAGNOSTICS INC.
“On June 9, 2022, Quest Diagnostics Incorporated (the “Company”) announced that Sam Samad will become Executive Vice President and Chief Financial Officer of the Company.”
Carrie Eglinton Manner resigned as Senior Vice President, Advanced and General Diagnostics and Clinical Solutions at QUEST DIAGNOSTICS INC.
“Carrie Eglinton Manner, the Company’s Senior Vice President, Advanced and General Diagnostics and Clinical Solutions, resigned from the Company effective June 3, 2022 to join OraSure Technologies, Inc.”
Helen I. Torley departed as Director at QUEST DIAGNOSTICS INC.
“On February 24, 2022, Dr. Helen I. Torley informed the Company of her decision to not seek re-election to the Company’s Board of Directors (the “Board”) at the Company’s Annual Meeting of Stockholders to be held May 18, 2022 (the “Annual Meeting”).”
James Davis was appointed as Chief Executive Officer–Elect at QUEST DIAGNOSTICS INC.
“port on Form 8-K/A amends the Original Report to provide information about the compensatory arrangements entered into in connection with the appointment of Mr. Davis as Chief Executive Officer–Elect.”
Mark J. Guinan departed as Executive Vice President and Chief Financial Officer at QUEST DIAGNOSTICS INC.
“Mark J. Guinan, the Company’s Executive Vice President and Chief Financial Officer, will retire in 2022.”
Stephen H. Rusckowski changed role as Executive Chairman at QUEST DIAGNOSTICS INC.
“Mr. Rusckowski, 64, currently Chairman, Chief Executive Officer and President, will continue to serve on the Board as Executive Chairman through March 2023.”
James E. Davis was appointed as Chief Executive Officer – Elect at QUEST DIAGNOSTICS INC.
“appointed James E. Davis, currently Executive Vice President, General Diagnostics, to be its next Chief Executive Officer and President, effective November 1, 2022. In addition, Mr. Davis was appointed Chief Executive Officer – Elect, effective February 3, 2022.”
Tracey C. Doi was elected as Director at QUEST DIAGNOSTICS INC.
“After considering the recommendation of the Board's Governance Committee, the Board elected Tracey C. Doi, Chief Financial Officer and Group Vice President of Toyota Motor North America, to fill the resulting vacancy, effective immediately.”
Tracey C. Doi was elected as Director at QUEST DIAGNOSTICS INC.
“the Board elected Tracey C. Doi, Chief Financial Officer and Group Vice President of Toyota Motor North America, to fill the resulting vacancy, effective immediately.”
Facts are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.